Ameera-1: Subgroup Analyses Of Phase I/Ii Study Of Amcenestrant (Sar439859), An Oral Selective Estrogen Receptor (Er) Degrader (Serd), With Palbociclib In Postmenopausal Women With Er Plus / Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Advanced Breast Cancer (Abc)